Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas
NCT03586024
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
WITHDRAWN
Status
OTHER
Sponsor class
Stopped
poor accrual
Conditions
Lymphoma
Interventions
DRUG:
Pembrolizumab
Sponsor
Abramson Cancer Center at Penn Medicine